vTv Therapeutics
VTVT
19 hedge funds and large institutions have $6.15M invested in vTv Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.6% more ownership
Funds ownership: 13.73% → 14.33% (+0.6%)
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
22% less capital invested
Capital invested by funds: $7.85M → $6.15M (-$1.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$292K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$64.9K |
| 3 |
SFCL
Strengthening Families & Communities LLC
Boston,
Massachusetts
|
+$4.12K |
| 4 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$1.19K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$477 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.6K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.62K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$682 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$259 |
VTVT Hedge Fund Activity: Q2 2024 in Review
19 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2024, worth a combined $6.15M — down 22% from $7.85M a quarter earlier.
Fund positioning in VTVT was balanced in Q2 2024: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $292K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $12.6K sold.
- 19 institutional investors held vTv Therapeutics (VTVT) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $6.15M of vTv Therapeutics stock for Q2 2024, down 22% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q2 2024 and 5 closed out, a net change of 0 holders.
- The largest vTv Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $292K added.
- The largest vTv Therapeutics seller in Q2 2024 was Tower Research Capital (TRC), an estimated $12.6K sold.
Based on aggregated 13F filings for Q2 2024.